MIF-based therapeutics, ranging from small molecule inhibitors to anti-MIF antibodies, have for instance showed promise in SLE, RA and cancer (Bloom et al., 2016; Bilsborrow et al., 2019). This evidence concerns the gene MIF and cancer.